Chakit Arora
Research Subjects
Research Interests
Chakit Arora has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Gajendra Pal Singh Raghava
Department of Computational Biology, Indraprastha Institute of Information Technology, India
12 shared publications - Dilraj Kaur
Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India
6 shared publications - Sumeet Patiyal
National Cancer Institute 1 Cancer Data Science Laboratory, Center for Cancer Research National Institutes of Health, Bethesda, Maryland
4 shared publications - Anjali Dhall
Department of Computational Biology, Indraprastha Institute of Information Technology, Okhla Phase 3, New Delhi 110020, India
3 shared publications - Anjali Lathwal
Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India
3 shared publications - Harpreet Kaur
Department of Computational Biology, Indraprastha Institute of Information Technology
3 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 15 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-23
Learning and actioning general principles of cancer cell drug sensitivity
High-throughput screening of drug sensitivity of cancer cell lines (CCLs) holds the potential to unlock anti-tumor therapies. In this study, we leverage such datasets to predict drug response using cell line transcriptomics, focusing on models’ interpretability and deployment on patients’ data. We use large language models (LLMs) to match drug to mechanisms of action (MOA)-related pathways. Genes crucial for prediction are enriched in drug-MOAs, suggesting that our models learn the molecular determinants of response. Furthermore, by using only LLM-curated, MOA-genes, we enhance the predictive accuracy of our models. To enhance translatability, we align RNAseq data from CCLs, used for training, to those from patient samples, used for inference. We validated our approach on TCGA samples, where patients’ best scoring drugs match those prescribed for their cancer type. We further predict and experimentally validate effective drugs for the patients of two highly lethal solid tumors, i.e., pancreatic cancer and glioblastoma.
- 15 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-23
Top Cited PapersOpen AccessLearning and actioning general principles of cancer cell drug sensitivity
High-throughput screening of drug sensitivity of cancer cell lines (CCLs) holds the potential to unlock anti-tumor therapies. In this study, we leverage such datasets to predict drug response using cell line transcriptomics, focusing on models’ interpretability and deployment on patients’ data. We use large language models (LLMs) to match drug to mechanisms of action (MOA)-related pathways. Genes crucial for prediction are enriched in drug-MOAs, suggesting that our models learn the molecular determinants of response. Furthermore, by using only LLM-curated, MOA-genes, we enhance the predictive accuracy of our models. To enhance translatability, we align RNAseq data from CCLs, used for training, to those from patient samples, used for inference. We validated our approach on TCGA samples, where patients’ best scoring drugs match those prescribed for their cancer type. We further predict and experimentally validate effective drugs for the patients of two highly lethal solid tumors, i.e., pancreatic cancer and glioblastoma.
- Open Access
Prognostic Biomarkers for Predicting Papillary Thyroid Carcinoma Patients at High Risk Using Nine Genes of Apoptotic Pathway
Objectives: Aberrant expression of apoptotic genes has been associated with papillary thyroid carcinoma (PTC) in the past, however, their prognostic role and utility as biomarkers remains poorly understood. Materials and methods: In this study, we analysed 505 PTC patients by employing Cox-PH regression techniques, prognostic index models and machine learning methods to elucidate the relationship between overall survival (OS) of PTC patients and 165 apoptosis related genes. Results: It was observed that nine genes (ANXA1, TGFBR3, CLU, PSEN1, TNFRSF12A, GPX4, TIMP3, LEF1, BNIP3L) showed significant association with OS of PTC patients. Five out of nine genes were found to be positively correlated with OS of the patients, while the remaining four genes were negatively correlated. These genes were used for developing risk prediction models. Our voting-based model achieved highest performance (HR=41.59, p=3.36×10 −4 , C=0.84, logrank-p=3.8×10 −8 ). The performance of voting-based model improved significantly when we used the age of patients with prognostic biomarker genes and achieved HR=57.04 with p=10 −4 (C=0.88, logrank-p=1.44×10 −9 ). We also developed classification models that can classify high risk patients (survival ≤ 6 years) and low risk patients (survival > 6 years). Our best model achieved AUROC of 0.92. Since these genes can also be used as potential therapeutic targets in PTC, we identified potential drug molecules which could modulate their expression profile. Conclusion: This study briefly revealed the key prognostic biomarker genes in the apoptotic pathway whose altered expression is associated with PTC progression and aggressiveness. In addition to this, risk assessment models proposed here can help in efficient management of PTC patients.
Open AccessPrognostic Biomarkers for Predicting Papillary Thyroid Carcinoma Patients at High Risk Using Nine Genes of Apoptotic Pathway
Objectives: Aberrant expression of apoptotic genes has been associated with papillary thyroid carcinoma (PTC) in the past, however, their prognostic role and utility as biomarkers remains poorly understood. Materials and methods: In this study, we analysed 505 PTC patients by employing Cox-PH regression techniques, prognostic index models and machine learning methods to elucidate the relationship between overall survival (OS) of PTC patients and 165 apoptosis related genes. Results: It was observed that nine genes (ANXA1, TGFBR3, CLU, PSEN1, TNFRSF12A, GPX4, TIMP3, LEF1, BNIP3L) showed significant association with OS of PTC patients. Five out of nine genes were found to be positively correlated with OS of the patients, while the remaining four genes were negatively correlated. These genes were used for developing risk prediction models. Our voting-based model achieved highest performance (HR=41.59, p=3.36×10 −4 , C=0.84, logrank-p=3.8×10 −8 ). The performance of voting-based model improved significantly when we used the age of patients with prognostic biomarker genes and achieved HR=57.04 with p=10 −4 (C=0.88, logrank-p=1.44×10 −9 ). We also developed classification models that can classify high risk patients (survival ≤ 6 years) and low risk patients (survival > 6 years). Our best model achieved AUROC of 0.92. Since these genes can also be used as potential therapeutic targets in PTC, we identified potential drug molecules which could modulate their expression profile. Conclusion: This study briefly revealed the key prognostic biomarker genes in the apoptotic pathway whose altered expression is associated with PTC progression and aggressiveness. In addition to this, risk assessment models proposed here can help in efficient management of PTC patients.
- Open Access
Pattern Recognition Receptor based Prognostic Biomarkers for predicting Survival of Uterine Corpus Endometrial Cancer Patients
In this study, we attempted to identify prognostic biomarkers for predicting survival risk of uterine corpus endometrial cancer (UCEC) patients from the gene expression profile of pattern recognition receptors (PRRs). A wide range of feature selection techniques have been tried, including network-based methods to identify a small number of genes from 331 PRR genes. Firstly, a risk stratification model has been developed using biomarker genes selected using a network-based approach and achieved HR=1.37 with p=0.294. Secondly, we developed a risk stratification model using biomarker of seven genes obtained from clustering and achieved HR=9.14 and p= 1.49×10 -12 . Finally, we developed various combinatorial models using biomarker of 15 PRR genes that were significantly associated with UCEC survival. We found that a multiple genes-based risk stratification model using nine genes (CLEC1B, CLEC3A, IRF7, CTSB, FCN1, RIPK2, NLRP10, NLRP9 and SARM1) gave the best result (HR=10.70, p=1.1×10 -12 , C=0.76, log-rank-p=8.15×10 -14 ). The performance of this model improved significantly when we used the clinical stage of patients in combination with the expression of nine genes and achieved HR=15.23 (p=2.21×10 -7 , C=0.78, log-rank-p=2.76×10 -17 ). We also developed classification models that can classify high-risk patients (survive ≤ 4.3 years) and low-risk patients (survive > 4.3 years) and achieved AUROC of 0.86. It was observed that specific genes are positively correlated with overall survival of UCEC patients. Based on these observations, we identified potential immunotherapeutic agents for treating UCEC patients.
Open AccessPattern Recognition Receptor based Prognostic Biomarkers for predicting Survival of Uterine Corpus Endometrial Cancer Patients
In this study, we attempted to identify prognostic biomarkers for predicting survival risk of uterine corpus endometrial cancer (UCEC) patients from the gene expression profile of pattern recognition receptors (PRRs). A wide range of feature selection techniques have been tried, including network-based methods to identify a small number of genes from 331 PRR genes. Firstly, a risk stratification model has been developed using biomarker genes selected using a network-based approach and achieved HR=1.37 with p=0.294. Secondly, we developed a risk stratification model using biomarker of seven genes obtained from clustering and achieved HR=9.14 and p= 1.49×10 -12 . Finally, we developed various combinatorial models using biomarker of 15 PRR genes that were significantly associated with UCEC survival. We found that a multiple genes-based risk stratification model using nine genes (CLEC1B, CLEC3A, IRF7, CTSB, FCN1, RIPK2, NLRP10, NLRP9 and SARM1) gave the best result (HR=10.70, p=1.1×10 -12 , C=0.76, log-rank-p=8.15×10 -14 ). The performance of this model improved significantly when we used the clinical stage of patients in combination with the expression of nine genes and achieved HR=15.23 (p=2.21×10 -7 , C=0.78, log-rank-p=2.76×10 -17 ). We also developed classification models that can classify high-risk patients (survive ≤ 4.3 years) and low-risk patients (survive > 4.3 years) and achieved AUROC of 0.86. It was observed that specific genes are positively correlated with overall survival of UCEC patients. Based on these observations, we identified potential immunotherapeutic agents for treating UCEC patients.
- Top Cited Papers
- 17 November 2020
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 22 (4)
AlgPred 2.0: an improved method for predicting allergenic proteins and mapping of IgE epitopes
AlgPred 2.0 is a web server developed for predicting allergenic proteins and allergenic regions in a protein. It is an updated version of AlgPred developed in 2006. The dataset used for training, testing and validation consists of 10 075 allergens and 10 075 non-allergens. In addition, 10 451 experimentally validated immunoglobulin E (IgE) epitopes were used to identify antigenic regions in a protein. All models were trained on 80% of data called training dataset, and the performance of models was evaluated using 5-fold cross-validation technique. The performance of the final model trained on the training dataset was evaluated on 20% of data called validation dataset; no two proteins in any two sets have more than 40% similarity. First, a Basic Local Alignment Search Tool (BLAST) search has been performed against the dataset, and allergens were predicted based on the level of similarity with known allergens. Second, IgE epitopes obtained from the IEDB database were searched in the dataset to predict allergens based on their presence in a protein. Third, motif-based approaches like multiple EM for motif elicitation/motif alignment and search tool have been used to predict allergens. Fourth, allergen prediction models have been developed using a wide range of machine learning techniques. Finally, the ensemble approach has been used for predicting allergenic protein by combining prediction scores of different approaches. Our best model achieved maximum performance in terms of area under receiver operating characteristic curve 0.98 with Matthew’s correlation coefficient 0.85 on the validation dataset. A web server AlgPred 2.0 has been developed that allows the prediction of allergens, mapping of IgE epitope, motif search and BLAST search (https://webs.iiitd.edu.in/raghava/algpred2/).
- 17 November 2020
- Published by Oxford University Press (OUP) in Briefings in Bioinformatics
- Vol. 22 (4)
Top Cited PapersAlgPred 2.0: an improved method for predicting allergenic proteins and mapping of IgE epitopes
AlgPred 2.0 is a web server developed for predicting allergenic proteins and allergenic regions in a protein. It is an updated version of AlgPred developed in 2006. The dataset used for training, testing and validation consists of 10 075 allergens and 10 075 non-allergens. In addition, 10 451 experimentally validated immunoglobulin E (IgE) epitopes were used to identify antigenic regions in a protein. All models were trained on 80% of data called training dataset, and the performance of models was evaluated using 5-fold cross-validation technique. The performance of the final model trained on the training dataset was evaluated on 20% of data called validation dataset; no two proteins in any two sets have more than 40% similarity. First, a Basic Local Alignment Search Tool (BLAST) search has been performed against the dataset, and allergens were predicted based on the level of similarity with known allergens. Second, IgE epitopes obtained from the IEDB database were searched in the dataset to predict allergens based on their presence in a protein. Third, motif-based approaches like multiple EM for motif elicitation/motif alignment and search tool have been used to predict allergens. Fourth, allergen prediction models have been developed using a wide range of machine learning techniques. Finally, the ensemble approach has been used for predicting allergenic protein by combining prediction scores of different approaches. Our best model achieved maximum performance in terms of area under receiver operating characteristic curve 0.98 with Matthew’s correlation coefficient 0.85 on the validation dataset. A web server AlgPred 2.0 has been developed that allows the prediction of allergens, mapping of IgE epitope, motif search and BLAST search (https://webs.iiitd.edu.in/raghava/algpred2/).
- 14 July 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (11) , 2743-2752
Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data
Purpose Intra-tumor heterogeneity and high mortality among patients with non-small-cell lung carcinoma (NSCLC) emphasize the need to identify reliable prognostic markers unique to each subtype. Methods In this study, univariate cox regression and prognostic index (PI)-based approaches were used to develop models for predicting NSCLC patients’ subtype-specific survival. Results Prognostic analysis of TCGA dataset identified 1334 and 2129 survival-specific genes for LUSC (488 samples) and LUAD (497 samples), respectively. Individually, 32 and 271 prognostic genes were found and validated in GSE study exclusively for LUSC and LUAD. Nearly, 9–10% of the validated genes in each subtype were already reported in multiple studies thus highlighting their importance as prognostic biomarkers. Strong literature evidence against these prognostic genes like “ELANE” (LUSC) and “AHSG” (LUAD) instigates further investigation for their therapeutic and diagnostic roles in the corresponding cohorts. Prognostic models built on five and four genes were validated for LUSC [HR = 2.10, p value = 1.86 × 10−5] and LUAD [HR = 2.70, p value = 3.31 × 10−7], respectively. The model based on the combination of age and tumor stage performed well in both NSCLC subtypes, suggesting that despite having distinctive histological features and treatment paradigms, some clinical features can be good prognostic predictors in both. Conclusion This study advocates that investigating the survival-specific biomarkers restricted to respective cohorts can advance subtype-specific prognosis, diagnosis, and treatment for NSCLC patients. Prognostic models and markers described for each subtype may provide insight into the heterogeneity of disease etiology and help in the development of new therapeutic approaches for the treatment of NSCLC patients.
- 14 July 2020
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 146 (11) , 2743-2752
Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data
Purpose Intra-tumor heterogeneity and high mortality among patients with non-small-cell lung carcinoma (NSCLC) emphasize the need to identify reliable prognostic markers unique to each subtype. Methods In this study, univariate cox regression and prognostic index (PI)-based approaches were used to develop models for predicting NSCLC patients’ subtype-specific survival. Results Prognostic analysis of TCGA dataset identified 1334 and 2129 survival-specific genes for LUSC (488 samples) and LUAD (497 samples), respectively. Individually, 32 and 271 prognostic genes were found and validated in GSE study exclusively for LUSC and LUAD. Nearly, 9–10% of the validated genes in each subtype were already reported in multiple studies thus highlighting their importance as prognostic biomarkers. Strong literature evidence against these prognostic genes like “ELANE” (LUSC) and “AHSG” (LUAD) instigates further investigation for their therapeutic and diagnostic roles in the corresponding cohorts. Prognostic models built on five and four genes were validated for LUSC [HR = 2.10, p value = 1.86 × 10−5] and LUAD [HR = 2.70, p value = 3.31 × 10−7], respectively. The model based on the combination of age and tumor stage performed well in both NSCLC subtypes, suggesting that despite having distinctive histological features and treatment paradigms, some clinical features can be good prognostic predictors in both. Conclusion This study advocates that investigating the survival-specific biomarkers restricted to respective cohorts can advance subtype-specific prognosis, diagnosis, and treatment for NSCLC patients. Prognostic models and markers described for each subtype may provide insight into the heterogeneity of disease etiology and help in the development of new therapeutic approaches for the treatment of NSCLC patients.
- Open Access
- 26 March 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 221
Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics
Human leukocyte antigen (HLA) are essential components of the immune system that stimulate immune cells to provide protection and defense against cancer. Thousands of HLA alleles have been reported in the literature, but only a specific set of HLA alleles are present in an individual. The capability of the immune system to recognize cancer-associated mutations depends on the presence of a particular set of alleles, which elicit an immune response to fight against cancer. Therefore, the occurrence of specific HLA alleles affects the survival outcome of cancer patients. In the current study, prediction models were developed, using 401 cutaneous melanoma patients, to predict the overall survival (OS) of patients using their clinical data and HLA alleles. We observed that the presence of certain favorable superalleles like HLA-B∗55 (HR = 0.15, 95% CI 0.034–0.67), HLA-A∗01 (HR = 0.5, 95% CI 0.3–0.8), is responsible for the improved OS. In contrast, the presence of certain unfavorable superalleles such as HLA-B∗50 (HR = 2.76, 95% CI 1.284–5.941), HLA-DRB1∗12 (HR = 3.44, 95% CI 1.64–7.2) is responsible for the poor survival. We developed prediction models using key 14 HLA superalleles, demographic, and clinical characteristics for predicting high-risk cutaneous melanoma patients and achieved HR = 4.52 (95% CI 3.088–6.609, p-value = 8.01E-15). Eventually, we also provide a web-based service to the community for predicting the risk status in cutaneous melanoma patients (https://webs.iiitd.edu.in/raghava/skcmhrp/).
- 26 March 2020
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 11, 221
Open AccessComputing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics
Human leukocyte antigen (HLA) are essential components of the immune system that stimulate immune cells to provide protection and defense against cancer. Thousands of HLA alleles have been reported in the literature, but only a specific set of HLA alleles are present in an individual. The capability of the immune system to recognize cancer-associated mutations depends on the presence of a particular set of alleles, which elicit an immune response to fight against cancer. Therefore, the occurrence of specific HLA alleles affects the survival outcome of cancer patients. In the current study, prediction models were developed, using 401 cutaneous melanoma patients, to predict the overall survival (OS) of patients using their clinical data and HLA alleles. We observed that the presence of certain favorable superalleles like HLA-B∗55 (HR = 0.15, 95% CI 0.034–0.67), HLA-A∗01 (HR = 0.5, 95% CI 0.3–0.8), is responsible for the improved OS. In contrast, the presence of certain unfavorable superalleles such as HLA-B∗50 (HR = 2.76, 95% CI 1.284–5.941), HLA-DRB1∗12 (HR = 3.44, 95% CI 1.64–7.2) is responsible for the poor survival. We developed prediction models using key 14 HLA superalleles, demographic, and clinical characteristics for predicting high-risk cutaneous melanoma patients and achieved HR = 4.52 (95% CI 3.088–6.609, p-value = 8.01E-15). Eventually, we also provide a web-based service to the community for predicting the risk status in cutaneous melanoma patients (https://webs.iiitd.edu.in/raghava/skcmhrp/).
- Open Access
- 30 January 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 71
A Hybrid Model for Predicting Pattern Recognition Receptors Using Evolutionary Information
This study describes a method developed for predicting pattern recognition receptors (PRRs), which are an integral part of the immune system. The models developed here were trained and evaluated on the largest possible non-redundant PRRs, obtained from PRRDB 2.0, and non-pattern recognition receptors (Non-PRRs), obtained from Swiss-Prot. Firstly, a similarity-based approach using BLAST was used to predict PRRs and got limited success due to a large number of no-hits. Secondly, machine learning-based models were developed using sequence composition and achieved a maximum MCC of 0.63. In addition to this, models were developed using evolutionary information in the form of PSSM composition and achieved maximum MCC value of 0.66. Finally, we developed hybrid models that combined a similarity-based approach using BLAST and machine learning-based models. Our best model, which combined BLAST and PSSM based model, achieved a maximum MCC value of 0.82 with an AUROC value of 0.95, utilizing the potential of both similarity-based search and machine learning techniques. In order to facilitate the scientific community, we also developed a web server “PRRpred” based on the best model developed in this study (http://webs.iiitd.edu.in/raghava/prrpred/).
- 30 January 2020
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 11, 71
Open AccessA Hybrid Model for Predicting Pattern Recognition Receptors Using Evolutionary Information
This study describes a method developed for predicting pattern recognition receptors (PRRs), which are an integral part of the immune system. The models developed here were trained and evaluated on the largest possible non-redundant PRRs, obtained from PRRDB 2.0, and non-pattern recognition receptors (Non-PRRs), obtained from Swiss-Prot. Firstly, a similarity-based approach using BLAST was used to predict PRRs and got limited success due to a large number of no-hits. Secondly, machine learning-based models were developed using sequence composition and achieved a maximum MCC of 0.63. In addition to this, models were developed using evolutionary information in the form of PSSM composition and achieved maximum MCC value of 0.66. Finally, we developed hybrid models that combined a similarity-based approach using BLAST and machine learning-based models. Our best model, which combined BLAST and PSSM based model, achieved a maximum MCC value of 0.82 with an AUROC value of 0.95, utilizing the potential of both similarity-based search and machine learning techniques. In order to facilitate the scientific community, we also developed a web server “PRRpred” based on the best model developed in this study (http://webs.iiitd.edu.in/raghava/prrpred/).
- Open Access
- 21 November 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 850677
Computing Skin Cutaneous Melanoma Outcome from the HLA-alleles and Clinical Characteristics
Human Leukocyte Antigen (HLA) is an essential component of the immune system which stimulates immune cells to provide protection and defense against cancer. More than thousands of HLA alleles have been reported in the literature; but, only a specific set of HLA alleles expressed in an individual. Recognition of cancer-associated mutations by the immune system depends on the presence of a particular set of alleles, that elicit an immune response to fight against cancer. It indicates that the occurrence of specific HLA alleles also affects the outcome of the cancer patients. In the current study, prediction models have been developed using 415 skin cutaneous melanoma (SKCM) patients for predicting the overall survival of patients from their HLA-alleles. It has been observed that, the presence of certain superalleles in the patients, is responsible for improved overall survival which were referred as favourable superalleles like HLA-B*55 (HR=0.15, 95% CI 0.034 to 0.67), HLA-A*01 (HR=0.5, 95% CI 0.3 to 0.8). In contrast, presence of certain superalleles in the patients is responsible for their poor survival, those superalleles were referred as unfavourable superalleles such as HLA-B*50 (HR=2.76, 95% CI 1.284 to 5.941), HLA-DRB1*12 (HR=3.44, 95% CI 1.64 to 7.2). We developed prediction models using 14 HLA-superalleles and five clinical characteristics for predicting high-risk SKCM patients and achieve HR=4.52 (95% CI 3.088-6.609) with p-value = 8.01E-15. Lastly, we provide a web-based service to community for predicting the risk in SKCM patients (https://webs.iiitd.edu.in/raghava/skcmhrp/)
- 21 November 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 850677
Open AccessComputing Skin Cutaneous Melanoma Outcome from the HLA-alleles and Clinical Characteristics
Human Leukocyte Antigen (HLA) is an essential component of the immune system which stimulates immune cells to provide protection and defense against cancer. More than thousands of HLA alleles have been reported in the literature; but, only a specific set of HLA alleles expressed in an individual. Recognition of cancer-associated mutations by the immune system depends on the presence of a particular set of alleles, that elicit an immune response to fight against cancer. It indicates that the occurrence of specific HLA alleles also affects the outcome of the cancer patients. In the current study, prediction models have been developed using 415 skin cutaneous melanoma (SKCM) patients for predicting the overall survival of patients from their HLA-alleles. It has been observed that, the presence of certain superalleles in the patients, is responsible for improved overall survival which were referred as favourable superalleles like HLA-B*55 (HR=0.15, 95% CI 0.034 to 0.67), HLA-A*01 (HR=0.5, 95% CI 0.3 to 0.8). In contrast, presence of certain superalleles in the patients is responsible for their poor survival, those superalleles were referred as unfavourable superalleles such as HLA-B*50 (HR=2.76, 95% CI 1.284 to 5.941), HLA-DRB1*12 (HR=3.44, 95% CI 1.64 to 7.2). We developed prediction models using 14 HLA-superalleles and five clinical characteristics for predicting high-risk SKCM patients and achieve HR=4.52 (95% CI 3.088-6.609) with p-value = 8.01E-15. Lastly, we provide a web-based service to community for predicting the risk in SKCM patients (https://webs.iiitd.edu.in/raghava/skcmhrp/)
- Open Access
A Hybrid Model for Predicting Pattern Recognition Receptors using Evolutionary Information
1. This study describes a method developed for predicting pattern recognition receptors (PRRs), which are an integral part of the immune system. The models developed here were trained and evaluated on the largest possible non-redundant PRRs, and non-pattern recognition receptors (Non-PRRs) obtained from PRRDB 2.0. Firstly, a similarity-based approach using BLAST was used to predict PRRs and got limited success due to a large number of no-hits. Secondly, machine learning-based models were developed using sequence composition and achieved a maximum MCC of 0.63. In addition to this, models were developed using evolutionary information in the form of PSSM composition and achieved maximum MCC value of 0.66. Finally, we developed hybrid models that combined a similarity-based approach using BLAST and machine learning-based models. Our best model, which combined BLAST and PSSM based model, achieved a maximum MCC value of 0.82 with an AUROC value of 0.95, utilizing the potential of both similarity-based search and machine learning techniques. In order to facilitate the scientific community, we also developed a web server “PRRpred” based on the best model developed in this study ( http://webs.iiitd.edu.in/raghava/prrpred/ ).
Open AccessA Hybrid Model for Predicting Pattern Recognition Receptors using Evolutionary Information
1. This study describes a method developed for predicting pattern recognition receptors (PRRs), which are an integral part of the immune system. The models developed here were trained and evaluated on the largest possible non-redundant PRRs, and non-pattern recognition receptors (Non-PRRs) obtained from PRRDB 2.0. Firstly, a similarity-based approach using BLAST was used to predict PRRs and got limited success due to a large number of no-hits. Secondly, machine learning-based models were developed using sequence composition and achieved a maximum MCC of 0.63. In addition to this, models were developed using evolutionary information in the form of PSSM composition and achieved maximum MCC value of 0.66. Finally, we developed hybrid models that combined a similarity-based approach using BLAST and machine learning-based models. Our best model, which combined BLAST and PSSM based model, achieved a maximum MCC value of 0.82 with an AUROC value of 0.95, utilizing the potential of both similarity-based search and machine learning techniques. In order to facilitate the scientific community, we also developed a web server “PRRpred” based on the best model developed in this study ( http://webs.iiitd.edu.in/raghava/prrpred/ ).